Newsfilter article unlocker

Operator

Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2026 Earnings Call. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to your host, Rob Brainin, Chief Executive Officer. You may begin.

Robert Brainin
CEO & Director

Good afternoon. I'm Rob Brainin, CEO of Champions Oncology, and I'm joined today by our CFO, David Miller. Thank you for joining our quarterly earnings call.

Before we begin, I'll remind you that today's remarks may include forward-looking statements. Actual results may differ materially, and more information can be found in our filings with the SEC. As many of you know, fiscal 2025 is a pivotal year for Champions as we rebounded after a difficult 2024 to achieve record annual revenue and profitability. Now as we move into fiscal year 2026, I'm honored to step into the role of leading Champions forward. My focus is on building on the strong foundation, sharpening strategic execution and positioning Champions for sustainable long-term growth.

Having been on the Board of Directors of Champions Oncology, I have been intimately involved with Ronnie in shaping the strategy, which is strong and will remain consistent. Together, we are committed to driving the large value opportunities we see in Corellia and in our data business while continuing to expand our core TOS platform, which remains the heart and soul of Champions.

Turning to the first quarter of fiscal 2026. The company delivered $14 million in revenue, rebounding from temporary softness in Q4. Growth was led by our TOS business